Skip to content
Our 2022 Year in Review is now live.
  • Insights

      Weekly Bulletin

      Your weekly recap of news and analysis from the psychedelic sector.

      Read the Latest

      Research Review

      A monthly review of the most important psychedelics research.

      Review Archive

      News & Interviews

      The latest news from across the psychedelics space.

      Explore Now
  • Data

      Psychedelics Patent Trackers

      We track the latest patents and filings related to psilocybin, MDMA and DMT.

      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents
      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents

      Psychedelic Legalization & Decriminalization Tracker

      Mapping psychedelic drug policy reform across the United States

      Explore the Tracker
      New: Oregon Local Jurisdiction Tracker

      Psychedelics Drug Development Tracker

      From drug discovery to regulatory approval, we map drug development in psychedelics.

      Explore the Tracker
  • Companies

      Stocks & Companies Directory

      A directory of all the major psychedelics stocks, companies and ETFs.

      Access Directory

      Sector Landscape Map

      Explore the Psychedelic Sector Landscape visually using our new tool.

      Explore Now

      Stock Watchlist

      A one-stop overview of psychedelics stocks financial performance.

      Explore Now
  • Psychedelic Careers
  • Contact
Search
Close
Read more about the article Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

  • Post published:July 20, 2022
  • Post category:Press Release
Read more about the article U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

  • Post published:June 17, 2022
  • Post category:Press Release
Read more about the article Mydecine Announces Reverse Stock-Split

Mydecine Announces Reverse Stock-Split

  • Post published:April 13, 2022
  • Post category:Press Release
Read more about the article Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

  • Post published:April 1, 2022
  • Post category:Press Release
Read more about the article Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement

Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement

  • Post published:March 31, 2022
  • Post category:Press Release
Read more about the article Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

  • Post published:March 24, 2022
  • Post category:Press Release
Read more about the article Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study

Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study

  • Post published:March 1, 2022
  • Post category:Press Release
Read more about the article Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

  • Post published:February 16, 2022
  • Post category:Press Release
Read more about the article Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada

Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada

  • Post published:February 8, 2022
  • Post category:Press Release
Read more about the article Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

  • Post published:February 3, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Psychedelic Stocks and Companies
  • News & Interviews
  • Psychedelic Sector Jobs
  • Data Bank

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

  • Psychedelic Alpha © 2022, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.